- Companies
- Orzax
Orzax Valuation Multiples
Orzax is valued at $387M as of September 2026, a 3.1x revenue multiple. In the last fiscal year, Orzax revenue was $150M and Orzax EBITDA was $40M.
Orzax Overview
About Orzax
Orzaks Ilac Ve Kimya Sanayi Ticaret AS operates as a sports nutrition brand. It manufactures, wholesales, stores, packs, imports, and exports all kinds of chemical, human, veterinary, and agricultural pharmaceuticals, as well as all kinds of food supplements for special nutritional purposes. Its product categories are Vitamin Series, Vitamin D Series, Mineral Series, Magnesium Series, Omega 3 Series, Plant Extracts, Immune Series, Probiotic Series, Bone And Joint Series, Supplements for Women, Beauty, Collagen Series, Supplements For Kids, GUMMIES SERIES, SPECIAL EDITION, and MOOD SERIES.
Founded
2004
HQ
Employees
N/A
Website
Financials (Last FY)
EV
$472M
Valuation Multiples
Start free trialOrzax Financials
Orzax reported last fiscal year revenue of $150M and EBITDA of $40M.
In the same fiscal year, Orzax generated $97M in gross profit, $40M in EBITDA, and $22M in net income.
Orzax P&L
In the most recent fiscal year, Orzax reported revenue of $150M and EBITDA of $40M.
Orzax is profitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 27%, and net margin of 14%.
Financial data powered by Morningstar, Inc.
Orzax Stock Performance
Orzax has current market cap of $387M, and enterprise value of $472M.
Orzax's stock price is $1.57.
Orzax share price increased by 130.5% in the last 30 days.
Orzax has an EPS (earnings per share) of $0.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $472M | $387M | 0.6% | 130.5% | - | - | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrzax Valuation Multiples
Orzax trades at 3.1x EV/Revenue multiple, and 11.8x EV/EBITDA.
Orzax Financial Valuation Multiples
As of September 24, 2026, Orzax has market cap of $387M and EV of $472M.
Orzax has a P/E ratio of 17.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Orzax Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Orzax Margins & Growth Rates
In the most recent fiscal year, Orzax reported gross margin of 65%, EBITDA margin of 27%, and net margin of 14%.
Orzax Margins
Orzax Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Orzax Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Orzax Competitors
Orzax competitors include Grape King Bio, Zhejiang Shouxiangu, Top Gum, Medy-Tox, Niagen Bioscience, Sido Muncul, Scitop Bio-tech, Biogena Good Vibes, Chong Kun Dang Holdings and Venture Life Group.
Most Orzax public comparables operate across Nutraceuticals & Cosmeceuticals.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $323M | $89M | 1.0x | 1.1x | 3.8x | 3.9x | |||
| $96M | $30M | 3.9x | 4.0x | 12.4x | - | |||
| $101M | ($8M) | 5.0x | - | (60.1x) | - | |||
| $182M | $19M | 2.1x | 2.0x | 20.0x | 14.4x | |||
| $129M | $18M | 1.3x | 1.3x | 9.9x | 11.2x | |||
| $229M | $94M | 2.4x | 2.6x | 6.0x | 7.4x | |||
| $55M | $18M | 9.0x | - | 28.1x | - | |||
| $143M | $21M | 5.7x | - | 39.0x | - | |||
This data is available for Pro users. Sign up to see all Orzax competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Orzax
| When was Orzax founded? | Orzax was founded in 2004. |
| Where is Orzax headquartered? | Orzax is headquartered in Turkey. |
| Who is the CEO of Orzax? | Orzax's CEO is Yunus Emre Alimoglu. |
| Is Orzax publicly listed? | Yes, Orzax is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Orzax? | Orzax trades under ORZAX ticker. |
| When did Orzax go public? | Orzax went public in 2026. |
| Who are competitors of Orzax? | Orzax main competitors include Grape King Bio, Zhejiang Shouxiangu, Top Gum, Medy-Tox, Niagen Bioscience, Sido Muncul, Scitop Bio-tech, Biogena Good Vibes, Chong Kun Dang Holdings, Venture Life Group. |
| What is the current market cap of Orzax? | Orzax's current market cap is $387M. |
| What is the current revenue of Orzax? | Orzax's last fiscal year revenue is $150M. |
| What is the current EV/Revenue multiple of Orzax? | Current revenue multiple of Orzax is 3.1x. |
| Is Orzax profitable? | No, Orzax is not profitable. |
| How many companies Orzax has acquired to date? | Orzax hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Orzax has invested to date? | Orzax hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Orzax
Lists including Orzax
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




